ACADIA Pharmaceuticals Inc. (ACAD) stock declined over -0.91% intraday to trade at $14.09 a share on NASDAQ. The stock opened with a gain of 0.36% at $14.03 and touched an intraday high of $14.31, falling -0.91% against the last close of $14.22. The stock went to a low of $13.95 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue484.14 Million
5Y Sales Change94.60%
Fiscal Year Ends2021-12-30
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock price is $14.09 as of the last check on Thursday, June 30. During the trading session, ACAD stock reached the peak price of $14.31 while $13.95 was the lowest point it dropped to.
The NASDAQ listed ACAD is part of Biotechnology industry that operates in the broader Health Care sector. ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Mr. James K. Kihara
VP, Corp. Controller & Principal Accounting Officer
Dr. Kathie M. Bishop Ph.D.
Sr. VP, Chief Scientific Officer & Head of Rare Disease
Mr. Stephen R. Davis J.D.
CEO & Director
Dr. Srdjan R. Stankovic M.D., M.S.P.H.
ACAD stock traded closed the last session at $14.09, which is $-0.13 or -0.91% lower than its previous close of $14.22. ACAD's current trading price is 15.11% lower than its 52-week high of $28.06 where as its distance from 52-week low of 12.24% is -49.78%.
Number of ACAD employees currently stands at -. ACAD operates from 12830 El Camino Real, Suite 400, San Diego, CA 92130, United States.
Official Webiste of $ACAD is: https://www.acadia-pharm.com
ACAD stock volume for the day was 1,592,185 shares while in the previous session number of ACAD shares traded was 1,577,837 . The average number of ACAD shares traded daily for last 3 months was 2.64 Million.
The percentage change in ACAD stock occurred in the recent session was -0.91% while the dollar amount for the price change in ACAD stock was $-0.13.
In the recent session, the day high for ACAD stock was $14.31 while the low for ACAD stock touched on the day was $13.95.
The market value of ACAD currently stands at 2.23 Billion with its latest stock price at $14.09 and 161.23 Million of its shares outstanding.